Clinical trial
Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT00096447 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00096447 |
|---|---|
| Title | Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer |
| Official title | A Phase II Evaluation Of Lapatinib (GW572016) (NCI-Supplied Agent, NSC #727989) In The Treatment Of Persistent Or Recurrent Endometrial Carcinoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Collaborators | Gynecologic Oncology Group |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Endometrial Carcinoma |
| Intervention type | Drug |
| Interventions | lapatinib ditosylate |
| Enrollment | 31 |
| Start date | Nov 1, 2004 |
| Primary completion | Mar 1, 2011 |
| Completion | Mar 1, 2011 |
| First posted | Nov 10, 2004 |
| Last update posted | Jul 24, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: